CAS: 30299-08-2; 2,2'-((Cyclohexane-1,1-Diylbis(4,1-Phenylene))Bis(Oxy))Bis(2-Methylbutanoic Acid)

该化合物是一种纤维酸衍生物,主要用作脂质低温剂.它的作用是激活透氧扩散者活性受体阿尔法(PPAR-α),它调节了脂质新陈代谢,导致血液流中的三氯丙烯酸和胆固醇水平下降. 氯硅酸酯因其双重极光效应而特别引人注目,它有效地降低了LDL和VLDL,同时适度地增加了HDL. 它的药用动力学特征包括口服生物利用率良好和延长半衰期,允许一次或两次日服用.该化合物在结构上优化,以尽量减少药物相互作用和不利影响,与以前的纤维酸盐相比. 克隆纤维酸盐通常用于超脂性贫血和混合性脂肪性贫血,在临床使用中提供平衡的功效和安全性特征.

结构式图片

上下游产品

2-(4-{1-[4-(1-Ethoxycarbonyl-1-methyl-propoxy)-phenyl]-cyclohexyl}-phenoxy)-2-methyl-butyric acid ethyl ester cyclohexanone phenol 2-Methylbutanoic acid 44H50N2O8C44H50N2O8

合成工艺路线路线简述

    📜环己酮置于盐酸,Potassium Carbonate,溶剂黄146,Sodium Hydroxide体系中,用 甲醇,水 作为反应溶剂,化学反应 6.5H,反应生成 克利贝特
    参考文献:高纯度克利贝特的制备方法
    标题:高纯度克利贝特的制备方法
    摘要:本发明涉及一种高纯度克利贝特的制备方法,属于药物化合物的制备领域.环己酮与苯酚在体积比为3:1~7:1的浓盐酸和冰醋酸中反应制得中间体ⅰ粗品,然后用单一溶剂脱色,降温析晶制得中间体ⅰ;2-甲基丁酸在三氯化磷中与液溴反应,再与无水乙醇反应,萃取,真空蒸馏,制得中间体ⅱ;无溶剂条件下中间体ⅰ和中间体ⅱ反应,制得中间体ⅲ;中间体ⅲ与氢氧化钠水解,萃取,析晶制得克利贝特粗品,再经过无水溶剂重结晶后制得克利贝特.本发明通过调整物料配比来缩短生产操作周期,能耗低,并且溶媒用量小,获得的产品结晶晶粒均匀,纯度高,成本低.

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-2025223262-A1
    优先权日:2022-03-31
    标 题 :Synthesis of morphinans with reduced herg activity and mop binding
    发明人:LAMMERT ECKHARD; SCHOLZ OKKA; OTTER SILKE; HEREBIAN DIRAN; HOFFMANN TORSTEN; SANZ MIGUEL ANGEL; KRAMP LAURENZ; LEVY LAURA MARIANA; HRISTEVA STANIMIRA
    权利人:HEINRICH HEINE UNIV DUESSELDORF; DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT E V; TAROS CHEMICALS GMBH & CO KG
    摘要:The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.

    专利号:US-7956214-B2
    优先权日:2001-11-02
    标题 :Process for the preparation of aniline-derived thyroid receptor ligands
    发明人:CHIDAMBARAM RAMAKRISHNAN; KANT JOYDEEP; WEAVER RAYMOND E; YU JURONG; GHOSH ARUN
    权利人:KAROBIO AB; BRISTOL MYERS SQUIBB CO
    摘要:Provided are processes for the synthesis of aniline derivatives, specifically certain aniline derivatives which have activity as thyroid receptor ligands.

    专利号:US-2024400552-A1
    优先权日:2016-11-11
    标题 :Heterocyclic modulators of lipid synthesis
    发明人:BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
    权利人:SAGIMET BIOSCIENCES INC
    摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Li JK, Lu C, Yang J, Li F, Ge J, Wei S, Xueqing L, Ding L, Ai-Dong W. Development of a LC-MS/MS method for the estimation of clinofibrate in human urine. Pharmazie. 2015 Apr;70(4):219-24. doi: 10.1016/j.jpba.2012.12.008. Epub 2012 Dec 20. doi: 10.1124/dmd.110.034454. Epub 2010 Sep 1. doi: 10.1107/S1600536809000427.
    6: Tomiyama N, Yasuda N, Iwano C, Matzno S, Matsuyama K. Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts. Clin Exp Pharmacol Physiol. 2007 Sep;34(9):876-80. Tokai J Exp Clin Med. 2005 Sep;30(3):149-55. Japanese. Japanese. Review. Erratum in: Drugs 1991 Dec;42(6):944.

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    参考文献:10.1046/j.1523-1755.1999.07133.x
    摘要:Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl. 1999 Jul;71():S134–6. doi: 10.1046/j.1523-1755.1999.07133.x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知